JPMorgan analyst Jessica Fye resumes coverage on BioCryst Pharma (NASDAQ: BCRX) with a Neutral rating and a price target of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage